Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis

Enright, 1994, Prevalence and correlates of respiratory symptoms and disease in the elderly, Chest, 106, 827, 10.1378/chest.106.3.827 Benson, 1998, Current estimates from the National Health Interview Survey, 1995, Vital Health Stat 10, 1 Murphy, 1992, Bacterial infection in chronic obstructive pulmonary disease, Am Rev Respir Dis, 146, 1067, 10.1164/ajrccm/146.4.1067 Chodosh, 1991, Treatment of acute exacerbations of chronic bronchitis: State of the art, Am J Med, 91, 87S, 10.1016/0002-9343(91)90317-Q Chodosh, 1992, Bronchitis and asthma, 476 Gump, 1976, Role of infection in chronic bronchitis, Am Rev Respir Dis, 113, 465 Kayser, 1992, Changes in the spectrum of organisms causing respiratory tract infections: A review, Postgrad Med J, 68, S17 Doern, 2001, Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999–2000, including a comparison of resistance rates since 1994–1995, Antimicrob Agents Chemother, 6, 1721, 10.1128/AAC.45.6.1721-1729.2001 Hoban, 2001, Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997–1999, Clin Infect Dis, 32, S81, 10.1086/320181 Thabaut, 1994, Interactions of ceftibuten with extended-spectrum beta-lactamases: A bacteriological and enzymatic analysis, Drugs Exp Clin Res, 20, 49 Niederman, 2001, Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention, Am J Respir Crit Care Med, 163, 1730, 10.1164/ajrccm.163.7.at1010 Siafakas, 1995, Optimal assessment and management of chronic obstructive pulmonary disease (COPD), Eur Respir J, 8, 1398, 10.1183/09031936.95.08081398 Saint, 1995, Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis, JAMA, 273, 957, 10.1001/jama.273.12.957 Balter, 1994, Recommendations on the management of chronic bronchitis: A practical guide for Canadian physicians, Can Med Assoc J, 10, 5 Ball, 1995, Epidemiology and treatment of chronic bronchitis and its exacerbations, Chest, 108, 43S, 10.1378/chest.108.2_Supplement.43S Wilson, 1999, Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis, J Antimicrob Chemother, 44, 501, 10.1093/jac/44.4.501 DeAbate, 1999, Efficacy and tolerability of once-daily grepafloxacin compared with clarithromycin in the treatment of acute bacterial exacerbations of chronic bronchitis, Clin Drug Invest, 17, 21, 10.2165/00044011-199917010-00003 DeAbate, 1999, Moxifloxacin in acute exacerbations of chronic bronchitis—a bacteriological meta-analysis Anzueto, 1998, Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: Ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d., Clin Ther, 20, 885, 10.1016/S0149-2918(98)80071-4 Lipsky, 1999, Treating acute bacterial exacerbations of chronic bronchitis in patients unresponsive to previous therapy: Sparfloxacin versus clarithromycin, Clin Ther, 21, 954, 10.1016/S0149-2918(99)80017-4 Notario, 1993, Comparative safety and efficacy of clarithromycin and three oral cephalosporins in the treatment of outpatients with bacterial bronchitis, Curr Ther Res Clin Exp, 54, 628, 10.1016/S0011-393X(05)80693-9 Skaer, 1996, Non-compliance with antihypertensive therapy. Economic consequences, Pharmacoeconomics, 9, 1, 10.2165/00019053-199609010-00001 Heffelfinger, 2000, Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group, Arch Intern Med, 160, 1399, 10.1001/archinte.160.10.1399